RomidepsinAn HDAC1, HDAC2, HDAC4, and HDAC6 inhibitor

Romidepsin (CAS 128517-07-7)

Romidepsin | CAS 128517-07-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_18, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364603, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 127ms
  • REVIEWS, PRODUCT
Synonym: Depsipeptide; Istodax; Chromadax
Application: An HDAC1, HDAC2, HDAC4, and HDAC6 inhibitor
CAS Number: 128517-07-7
Purity: ≥98%
Molecular Weight: 540.70
Molecular Formula: C24H36N4O6S2
* Refer to Certificate of Analysis for lot specific data (including water content).
submit a review for this product and receive 15 cruzcredits

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines.

Physical State :
Solid
Solubility :
Soluble in DMSO (10 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), methanol, and chloroform.
Storage :
Store at -20° C
Melting Point :
219-224 °C
Boiling Point :
~942.8 °C at 760 mmHg (Predicted)
Density :
~1.2 g/cm3 (Predicted)
Refractive Index :
n20D 1.53 (Predicted)
IC50 :
HDAC1: IC50 = 0.2 nM (human); HDAC2: IC50 = 1 nM (human); Histone deacetylase 3/Nuclear receptor corepressor 2 : IC50 = 3 nM (human); HDAC6: IC50 = 0.2 µM (human); HDAC4: IC50 = 0.51 µM (human)
pK Values :
pKa: 11.33 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
YV9399000
PubChem CID :
5352062
MDL Number :
MFCD18433404
SMILES :
C/C=C1/C(=O)N[C@H](C(=O)O[C@H]2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 108ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Barbarotta et al Barbarotta et al. (PubMed ID 26413372) found that single-agent therapy using the histone deacetylase inhibitor, romidepsin, can lead to durable responses in patients with relapsed/refractory peripheral T-cell lymphoma. -SCBT Publication Review
Date published: 2015-03-27
  • y_2019, m_9, d_18, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364603, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.